![Acticor Biotech](/common/images/company/EU_ALACT.png)
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...
Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies...
Regulatory News: This replaces the announcement made at 17:45 on October 31 because the following statement has been deleted: “The limited review procedures for the interim financial statements...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.25 | 0.25 | 0.25 | 0 | 0 | DE |
4 | 0 | 0 | 0.25 | 0.25 | 0.25 | 0 | 0 | DE |
12 | -0.082 | -24.6987951807 | 0.332 | 0.369 | 0.23 | 4805 | 0.29468809 | DE |
26 | -0.17 | -40.4761904762 | 0.42 | 0.89 | 0.22 | 27558 | 0.52202246 | DE |
52 | -4.15 | -94.3181818182 | 4.4 | 5.3 | 0.22 | 49984 | 0.8789887 | DE |
156 | -5.85 | -95.9016393443 | 6.1 | 11 | 0.22 | 18801 | 1.52834666 | DE |
260 | 0.059 | 30.890052356 | 0.191 | 11 | 0.142 | 58526 | 1.26889766 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約